
Neoprobe completes sale of device business; plans to change name
In a deal that marks its transformation to a pure-play radiopharmaceutical company, Neoprobe (NYSE Amex:NEOP) has completed the sale of its radiation detection business to Devicor Medical Products. The deal’s value could reach $50 million for Dublin, Ohio-based Neoprobe — $30 million up front and $20 million in royalties if Devicor’s sales of the acquired […]